Royce & Associates’s Medifast MED Stock Holding History

Royce & Associates’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,462	Closed	-$633K	–	914
2023 Q3	$633K	Buy	+8,462	New	+$751K	0.01%	786
2015 Q4	–	Sell	-1,400	Closed	-$38K	–	1155
2015 Q3	$38K	Hold	1,400	–	–	﹤0.01%	1167
2015 Q2	$45K	Hold	1,400	–	–	﹤0.01%	1185
2015 Q1	$42K	Sell	1,400 -800	-36%	-$25.4K	﹤0.01%	1200
2014 Q4	$74K	Buy	2,200 +1,400	+175%	+$43.6K	﹤0.01%	1237
2014 Q3	$26K	Sell	800 -59,200	-99%	-$1.82M	﹤0.01%	1377
2014 Q2	$1.82M	Sell	60,000 -108,000	-64%	-$3.37M	0.01%	1051
2014 Q1	$4.89M	Hold	168,000	–	–	0.01%	879
2013 Q4	$4.39M	Hold	168,000	–	–	0.01%	896
2013 Q3	$4.52M	Buy	168,000 +13,000	+8%	+$348K	0.01%	874
2013 Q2	$3.99M	Buy	+155,000	New	+$4.07M	0.01%	904

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Royce & Associates's MED Position: Q4 2023 in Review

Royce & Associates sold out of Medifast (MED) in Q4 2023, closing a stake of 8,462 shares — an estimated $633K sold.

Royce & Associates first reported a position in MED in Q2 2013 and held it in 11 quarters. The position peaked at $4.89M in Q1 2014. 216 funds tracked by Wall St. Rank hold MED as of Q4 2023.

Royce & Associates reported no remaining Medifast position as of Q4 2023 after selling out during the quarter.
Royce & Associates sold 8,462 Medifast shares in Q4 2023, an estimated $633K.
Royce & Associates first reported a position in Medifast in Q2 2013 and held it in 11 quarters.
Royce & Associates's Medifast position peaked at $4.89M in Q1 2014.
216 funds tracked by Wall St. Rank held Medifast as of Q4 2023.

Based on Royce & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.